Skip to main content

13-09-2022 | ESMO 2022 | Conference coverage | Video

Latest EV-103 update further supports enfortumab vedotin for untreated advanced UC

share
SHARE

Jonathan Rosenberg presents data from a randomized noncomparative cohort of the EV-103 trial of enfortumab vedotin, investigating the agent alone or together with pembrolizumab as a first-line option for cisplatin-ineligible patients with advanced urothelial carcinoma (3:20).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany